NCT05306132

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

A Phase I ,Open, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is the first-in-human of ASKC202, which is an open-label, non-randomized, multicenter study with a dose escalation phase and a dose expansion phase.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	ASKC202	Dosage Forms: Tablets; Administration: Oral administration
DRUG	ASK120067	Dosage Forms: Tablets; Administration: Oral administration

Timeline

• Start date: 2022-08-08
• Primary completion: 2026-12-01
• Completion: 2027-12-01
• First posted: 2022-03-31
• Last updated: 2025-12-23

Locations

3 sites across 1 country: China